34 results on '"Shimoda, Haruko"'
Search Results
2. Thrombohemorrhagic events, disease progression, and survival in polycythemia vera and essential thrombocythemia: a retrospective survey in Miyazaki prefecture, Japan
3. Loss of TET2 has dual roles in murine myeloproliferative neoplasms: disease sustainer and disease accelerator
4. Prognosis of Indolent Adult T-Cell Leukemia/Lymphoma
5. R723, a selective JAK2 inhibitor, effectively treats JAK2V617F-induced murine myeloproliferative neoplasm
6. Potentiated activation of VLA-4 and VLA-5 accelerates proplatelet-like formation
7. Acute myeloid leukemia in clinical practice: a retrospective population-based cohort study in Miyazaki Prefecture, Japan
8. Clinical features and treatment outcomes of isolated secondary central nervous system lymphomas in Miyazaki Prefecture
9. Real-World Data on Clinical Features, Outcomes, and Prognostic Factors in Multiple Myeloma from Miyazaki Prefecture, Japan
10. Higher average chemotherapy dose intensity improves prognosis in patients with aggressive adult T‐cell leukemia/lymphoma
11. JAK2 V617F uses distinct signalling pathways to induce cell proliferation and neutrophil activation
12. The impact of cytogenetic abnormalities on the prognosis of primary myelofibrosis: a prospective survey of 202 cases in Japan
13. Chronic thrombopoietin overexpression induces mesangioproliferative glomerulopathy in mice
14. Higher average chemotherapy dose intensity improves prognosis in patients with aggressive adult T‐cell leukemia/lymphoma.
15. Outcome of allogeneic hematopoietic cell transplantation in patients with adult T-cell leukemia
16. Effects of mogamulizumab in adult T-cell leukemia/lymphoma in clinical practice
17. Differences in Hematological and Clinical Features Between Essential Thrombocythemia Cases With JAK2- or CALR-Mutations
18. TET2 mutation in diffuse large B-cell lymphoma
19. TET2 Mutation in Adult T-Cell Leukemia/Lymphoma
20. Therapies Targeting the MAPK Pathway Improve Bone Marrow (BM) Fibrosis Induced By JAK2V617F
21. TET2 Is Essential for Survival in Mice, and Decreased TET2 Expression Enlarges HSC Compartment and Alters Cell Differentiation
22. Clinical features and treatment outcomes of isolated secondary central nervous system lymphomas in Miyazaki Prefecture
23. NS-018, a Potent Novel JAK2 Inhibitor, Effectively Treats Murine MPN Induced by the Janus Kinase 2 (JAK2) V617F Mutant
24. Potentiated Activation of VLA-4 and VLA-5 Accelerates Proplatelet-Like Formation In Megakaryocytes.
25. Tyrosine kinase 2 interacts with the proapoptotic protein Siva-1 and augments its apoptotic functions
26. JAK2V617F Mutation Selectively Exerts the STAT3 Pathway for Enhancing a Neutrophil Activation Marker.
27. Absence of Somatically Acquired JAK1 Mutations in Adult T-Cell Leukemia/Lymphoma.
28. Efficacy of R723, a Potent and Selective JAK2 Inhibitor, in JAK2V617F-Induced Murine MPD Model.
29. Elevated Leukocyte Alkaline Phosphatase Scores Induced by Jak2 V617F Mutation
30. Expression of V617F JAK2 in Mice Leads to MPD Mimicking Human ET, Idiopahtic Myelofibrosis, and PV.
31. Real-World Data on Clinical Features, Outcomes, and Prognostic Factors in Multiple Myeloma from Miyazaki Prefecture, Japan.
32. JAK2V617FMutation Selectively Exerts the STAT3 Pathway for Enhancing a Neutrophil Activation Marker.
33. Loss of Tyrosine Kinase 2 Does Not Affect the Severity of Jak2 V617F-induced Murine Myeloproliferative Neoplasm.
34. [Antiphospholipid syndrome with autoimmune hemolytic anemia which mimics thrombotic thrombocytopenic purpura].
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.